Urology News and Research

Latest Urology News and Research

Nocturnal incontinence poses major burden after female bladder reconstruction

Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research.

22 Apr 2014

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.

21 Apr 2014

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis plc and Forest Laboratories, Inc. today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest.

18 Apr 2014

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development

18 Apr 2014

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression.

16 Apr 2014

Community efforts boost people for HIV testing and reduce new infections

Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal The Lancet Global Health.

16 Apr 2014

Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

Urologists at Rush University Medical Center are the first in Chicago to offer a powerful new tool for visualizing and monitoring the prostate in men who have high prostate-specific antigen (PSA) levels and in detecting prostate cancer more accurately.

15 Apr 2014

Adjuvant radiotherapy after prostatectomy ‘risks urinary incontinence’

Men who receive adjuvant radiation therapy following radical prostatectomy face a significantly increased risk of urinary incontinence in the following years, study findings indicate.

14 Apr 2014

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women.

8 Apr 2014

Patient-friendly examination method reduces need for prostate cancer biopsies

Each year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer.

8 Apr 2014

Bladder outlet obstruction shows distinct urodynamic patterns

Chinese researchers have identified a number of distinct urodynamic patterns among older men with non-neurogenic lower urinary tract symptoms and bladder outlet obstruction.

7 Apr 2014

ICIQ bladder diary ‘psychometrically valid’

UK researchers in collaboration with patients and clinicians have developed a new diary to be used to record lower urinary tract symptoms.

7 Apr 2014

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.

3 Apr 2014

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.

1 Apr 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Scientists move a step closer to preserving fertility in young boys with cancer

Scientists have moved a step closer to being able to preserve fertility in young boys who undergo chemotherapy and radiation treatments for cancer. The new research, published in Fertility and Sterility, the journal of the American Society for Reproductive Medicine, addresses the safety of an option scientists are developing for boys who aren't sexually mature and cannot bank sperm.

28 Mar 2014

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance.

25 Mar 2014

Prostate stiffness is a risk factor for voiding dysfunction

Prostate elasticity is an independent risk factor for urinary voiding symptoms, although not for lower urinary tract symptoms in general or storage symptoms, clinical research indicates.

24 Mar 2014